Actively Recruiting
18F-mFBG PET Imaging in the Evaluation of Neuroblastoma
Led by First Affiliated Hospital of Zhejiang University · Updated on 2025-08-08
200
Participants Needed
1
Research Sites
251 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The aim of this study is to evaluate the diagnostic performance and tumor burden of 18F-metafluorobenzylguanidine (18F-MFBG) positron emission tomography (PET) in patients with neuroblastoma.
CONDITIONS
Official Title
18F-mFBG PET Imaging in the Evaluation of Neuroblastoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 0 to 18 years old with a legal guardian
- Clinically suspected or confirmed neuroblastoma
- If under 8 years old or unable to write, guardian must understand and comply with study requirements
- If 8 years old or older and able to write, both patient and guardian must sign informed consent
You will not qualify if you...
- Severe primary diseases such as heart, brain, liver, kidney, or blood system diseases
- Ionizing radiation exposure exceeding 50 mSv in the past year outside this study
- Use of experimental drugs or devices within the past month
- Any condition deemed potentially harmful by the principal investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The First Affiliated Hospital of Zhejiang University School of Medicine
Hangzhou, Zhejiang, China, 310003
Actively Recruiting
Research Team
P
Peipei Wang, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here